News
Eisai and Biogen present promising lecanemab study results
Eisai and Biogen have announced the results from Eisai’s global phase 3 confirmatory Clarity Alzheimer’s disease (AD) clinical study of lecanemab. Results were presented at the 2022 Clinical Trials on Alzheimer’s Disease conference.